Home › Policy by country › The Cass Review explained

The Cass Review explained

The Cass Review is the most thorough independent investigation into paediatric gender care carried out to date. It was led by paediatrician Dr Hilary Cass at the request of NHS England and culminated in April 2024 in a final report that fundamentally called the affirmation-only model for minors into question. The report led to the closure of the Tavistock GIDS clinic, a ban on puberty blockers outside research settings and a restructuring of the entire English care pathway. The consequences reach well beyond the United Kingdom.

Background: the crisis around GIDS and Tavistock

The Gender Identity Development Service (GIDS) of the Tavistock and Portman NHS Foundation Trust was for almost three decades the only specialised centre for gender care for minors in England and Wales. From around 2014 the number of referrals exploded: from a few dozen per year to thousands, with a striking shift towards adolescent girls who only began identifying as trans during puberty. At the same time, multiple whistleblowers from within the service — including psychotherapist David Bell and former GIDS clinicians Anna Hutchinson and Marcus Evans — went public with concerns about rushed diagnostics, missing follow-up and the side-lining of comorbid problems such as autism, trauma and depression.

The case Bell vs Tavistock (2020) — brought by detransitioner Keira Bell — led to a ruling in which the British High Court held that minors are almost never capable of 'Gillick-competent' consent to puberty blockers. That ruling was procedurally overturned on appeal, but the questions raised remained. In 2020 NHS England therefore commissioned a broad independent investigation. In 2022 the Care Quality Commission rated GIDS as 'inadequate'. In 2023 the clinic was closed.

Methodology: systematic reviews via York

What makes the Cass Review distinctive is its scientific methodology. The University of York carried out, on Cass's behalf, a series of systematic literature reviews into every aspect of paediatric gender care: puberty suppression, cross-sex hormones, psychological interventions, social transition, international guidelines and epidemiology. These reviews have been published in peer-reviewed journals, including Archives of Disease in Childhood. The full final report is available via the UK National Archives.

The conclusion of the York reviews was devastating: of the 103 studies into puberty blockers and hormones for young people, only a handful met minimum quality criteria. The evidence for positive effects on mental wellbeing was described by Cass as 'remarkably weak'. It also turned out that the international guidelines — including those of WPATH and the Endocrine Society — largely cross-reference each other without new primary studies underlying them ('circular underpinning').

Key findings

• The scientific evidence for medical treatment of gender dysphoria in minors is weak. There is no evidence that puberty blockers improve young people's mental health; original claims of improved functioning are not replicable.
• Puberty blockers are not the 'reversible pause button' as long presented. Almost all young people treated (around 98%) progress to cross-sex hormones, suggesting that blockers do not pause development but rather lock it in.
• The patient population has changed radically since 2010: from a small number of boys with early-childhood dysphoria to a large group of adolescent girls with comorbid psychiatric problems, autism-spectrum traits and extensive internet use.
• Diagnostic rigour at GIDS fell seriously short. Comorbidity was insufficiently investigated; social and family context insufficiently weighed.
• There is no reliable follow-up of patients. Cass attempted a data-linkage study with the six English adult gender clinics, but five of the six refused to cooperate — a circumstance Cass explicitly flags as disturbing.
• Social transition in children is not a neutral intervention but a psychosocial act that can influence the natural course. The review explicitly advises caution here.
• The 'affirmation-only' approach — in which the child's self-reported identity is the starting point — is not evidence-based and can obscure other underlying causes.

Recommendations

• Closure of GIDS and establishment of regional centres focused on holistic mental health care, not medical transition.
• Puberty blockers only within strict clinical research; no routine prescribing.
• Cross-sex hormones under 18 with 'extreme caution', and certainly not under 16.
• Extensive screening for autism, ADHD, trauma, depression and eating disorders before a gender diagnosis is considered.
• Recognition that a substantial proportion of young people grow out of dysphoria during adolescence (desistance); medical haste is incompatible with this course.
• Strict registration and lifelong follow-up of every patient treated.
• More research into the causes of the explosive rise in referrals, including social and media factors.

Response from NHS England and the British government

NHS England adopted the recommendations in full. The official NHS response describes the transition to regional centres and the discontinuation of puberty blockers outside study settings. The British government made the ban on puberty blockers for clinical use in minors permanent — see the UK government announcement. Private prescriptions have also been restricted.

Consequences for the Netherlands

The Cass Review is politically and scientifically sensitive for the Netherlands, because the English model was for years based on the Dutch Protocol. The York reviews pointed out that the original Dutch research (de Vries, Cohen-Kettenis, Steensma) rested on small, selected samples without a control group, and that the results were not replicable in other countries. See also the Dutch Protocol.

The Dutch professional field has so far not started a formal evaluation along the English lines, but Amsterdam UMC and Radboudumc have tacitly tightened their indication criteria. Zorginstituut Nederland is currently assessing whether puberty suppression for gender dysphoria still belongs in the basic health insurance package. The Dutch House of Representatives held several debates in 2024 and 2025 in which the Cass Review was prominently cited.

International impact

The report confirms and reinforces earlier policy in Sweden (SBU, Karolinska), Finland (COHERE) and Norway (UKOM). Denmark followed in 2024 with similar tightenings. In Australia, Queensland and South Australia have suspended new referrals for minors pending evaluations that explicitly cite Cass. The Cass Review also plays a role in legal and political debate in parts of Canada and the US.

Criticism and rebuttal

Activist organisations and parts of WPATH criticised the review as 'transphobic' or methodologically incomplete. Cass and the York team answered this criticism point by point and pointed out that most critical publications have themselves not gone through peer review or contain conflicts of interest — see the WPATH Files, which revealed that WPATH suppressed its own systematic reviews when the outcomes were inconvenient. The British parliament took the findings seriously across party lines. For a more extensive discussion of the critical line, see critical perspectives on gender care.